Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.

NCT07389265 is registered in ClinicalTrials.gov with University of Campania Luigi Vanvitelli as lead sponsor.

NCT NCT07389265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07389265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAPRI-3 GOIM Study: Phase 3 Clinical Study to Evaluate the Use of Continuing Cetuximab Treatment Beyond First Line Progression in Molecular Selected Metastatic Colorectal Cancer Patients.
Lead sponsor
University of Campania Luigi Vanvitelli
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2025
Completion date
October 31, 2030
Enrollment
480 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (mcrc)